{
  "eval_id": "S11",
  "timestamp": "2025-09-19T09:01:55.826598+00:00",
  "model": "gpt-4o",
  "temperature": 0.6,
  "rep_input": "Clinically, what are the on-label points I should know about Trodelvy in HR+/HER2- after prior CDK4/6?",
  "model_output": "Trodelvy is indicated for HR+/HER2- metastatic breast cancer after progression on or after at least two prior systemic therapies, including endocrine therapy and a CDK4/6 inhibitor. It's important to consider the patient's performance status and overall treatment goals when evaluating this option. Please send the EMA SmPC for further details."
}